Radiation Oncology MarketSize, Share & Industry Analysis, 2026-2034By Treatment ModalityBy TechniqueBy Product and Service OfferingBy Cancer TypeBy Treatment IntentBy Fractionation RegimenBy End UserBy Patient Age GroupBy Procurement Model
Full title & scope — all 9 axes with their segments
Radiation Oncology Market Size, Share & Industry Analysis, By Treatment Modality (External Beam Radiation Therapy, Proton Therapy, Carbon Ion Therapy, Brachytherapy, Systemic Radioisotope Therapy, Intraoperative Radiotherapy), By Technique (3D Conformal Radiotherapy, Intensity-Modulated Radiotherapy, Volumetric Modulated Arc Therapy, Image-Guided Radiotherapy, Stereotactic Radiotherapy, Adaptive Radiotherapy), By Product and Service Offering (Treatment Delivery Systems, Treatment Planning Software, Oncology Information Systems, Patient Positioning and Immobilization, Quality Assurance and Dosimetry, Radioisotopes and Sealed Sources, Installation, Maintenance and Upgrade Services), By Cancer Type (Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Brain and Central Nervous System Tumors, Gynecological Cancer, Other Cancers), By Treatment Intent (Curative, Adjuvant, Neoadjuvant, Palliative), By Fractionation Regimen (Conventional Fractionation, Moderate Hypofractionation, Ultra-Hypofractionation, Hyperfractionation, Accelerated Fractionation), By End User (Hospitals, Independent Radiotherapy Centers, Cancer Research Institutes, Ambulatory Oncology Clinics), By Patient Age Group (Pediatric, Adult, Geriatric), By Procurement Model (Outright Purchase, Leasing and Equipment-as-a-Service, Per-Procedure or Managed Service Contracts, Public Tender and Government Procurement), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The size was built upward from the number of treatment courses delivered each year, the split of those courses by modality and technique, and the realised revenue per course across equipment, software, services and radioisotopes. Equipment revenue was set from linear accelerator and particle system installations and replacement cycles, then paired with service contracts that follow the installed base. Isotope and sealed source sales were built from treatment volumes and unit prices. The result was then checked against disclosed segment revenue from the listed suppliers. Where the two views disagreed, the bottom-up assumptions on installations, course volumes or realised prices were corrected, and the top-down figure was not averaged in.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target radiation oncologists, medical physicists and department administrators who specify equipment, along with hospital procurement and biomedical engineering leads who run tenders. Supplier-side conversations cover product management, regional sales and service heads at equipment, software and isotope companies. Reimbursement and health technology assessment contacts add the payer view on hypofractionation and proton coverage. Questions focus on replacement timing, machine utilisation, pricing and tender outcomes. Sampling emphasises North America, Western Europe, China, Japan and India, which hold the largest installed bases and the fastest capacity additions, with smaller coverage of the Gulf states and Brazil.
Desk research draws on the FDA 510(k) and premarket approval databases and the European EUDAMED registry for device clearances, the IAEA Directory of Radiotherapy Centres for installed base, and the Particle Therapy Co-operative Group facility list for proton and carbon ion sites. Cancer incidence comes from the IARC GLOBOCAN estimates and national registries such as SEER. Reimbursement rates come from the CMS Physician Fee Schedule and hospital outpatient payment rules. Company annual reports, SEC filings and investor presentations supply segment revenue, and national tender portals provide award values.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast projects treatment volumes from cancer incidence and the growth in radiotherapy utilisation, then applies the expected shift in mix toward stereotactic, adaptive and proton delivery and shorter fractionation schedules. Equipment demand follows planned replacement of ageing accelerators and funded capacity additions in Asia Pacific and the Gulf. Hardware prices are held broadly flat, with a modest uplift for software and services. For the forecast to hold, reimbursement must keep supporting hypofractionation without sharp cuts to per-course payment, radioisotope supply must scale with radioligand demand, and staffing must not cap the use of new machines.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
The 2020 to 2025 series was back-tested against reported supplier segment revenue and recorded installation counts, and the implied historical growth was compared with the modelled rate to confirm that the gap was explained by mix and pricing. Segment shifts, in particular proton, stereotactic and radioisotope growth, were reviewed with clinical and commercial specialists. Sensitivities covered a delay in proton project financing, slower uptake of radioligand therapy and a swing in hardware pricing, and each was run through the bull and bear cases to confirm their ordering and spread.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
The estimate is firmest for external beam equipment, software and services, where public company disclosures and installed base records are plentiful. It is weaker for systemic radioisotope therapy, carbon ion therapy and per-procedure contracts, where adoption is early, reporting is thin and a few projects can move a year's total. Country splits in the Middle East and Africa and in Latin America carry the widest band. A revision would follow a change in reimbursement for hypofractionation, a delay in major proton projects or a shortfall in isotope supply. A band of plus or minus fifteen percent on the base year total is reasonable.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Radiation Oncology Market projected to reach?
USD 18.7 USD Billion by 2034, CAGR 7.48%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 41% of global revenue through 2034.
05Which segment leads the market?
External Beam Radiation Therapy is the largest line by treatment modality, at 72% of revenue in 2025.
06Who are the key companies profiled?
Siemens Healthineers AG (Varian Medical Systems, Inc.), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mevion Medical Systems, Inc., Brainlab AG, RaySearch Laboratories AB, Mirion Technologies, Inc. (Sun Nuclear), Eckert & Ziegler SE, Novartis AG, Bayer AG, Perspective Therapeutics, Inc., Theragenics Corporation, CIVCO Medical Solutions, Best Medical International, Inc., PTW-Freiburg GmbH, Standard Imaging, Inc., Reflexion Medical, Inc., Our United Corporation, Shinva Medical Instrument Co., Ltd., ProTom International Holding Corp., Leo Cancer Care, Inc., ZAP Surgical Systems, Inc., iCAD, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.